GREENWICH LIFESCIENCES INC
GLSINASDAQTrading Snapshot
- Day Range
- $15.43 – $15.81
- 52-Week Range
- $7.78 – $34.10
- Volume
- $3.54B
- Avg Volume
- $4.27B
- Shares Outstanding
- 14.7M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $18M
- Last Q Revenue
- $5M
- P/E Ratio
- -10.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.48
- Dividend Yield
- 0.00%
Why Investors Own GLSI
- ✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GREENWICH LIFESCIENCES INC
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom. The Company's application to expand FLAMINGO-01 into the UK has been formally approved by UK regulators, thus adding po
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price target from $50 to $69.
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me
Greenwich LifeSciences remains a high-risk microcap, with continued skepticism despite recent trial and enrollment updates. Click for more on GLSI stock.
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modificati
Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.FLAMINGO-01 Steering Committee Clinical StrategyOn December 22, 2025, the